首页 > 最新文献

中华妇产科杂志最新文献

英文 中文
[Age-stratified association between preconception body mass index and risk of macrosomia at delivery]. [孕前体重指数与分娩时巨大儿风险之间的年龄分层关联]。
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20240807-00439
S W Wu, N Zhang
<p><p><b>Objective:</b> To investigate the impact of preconception body mass index (BMI) on neonatal birth weight and the risk of macrosomia in pregnant women across various age groups. <b>Methods:</b> A cohort study was conducted, selecting pregnant women who underwent their initial prenatal assessment at Beijing Obstetrics and Gynecology Hospital from September 1st, 2018 to March 31st, 2020. Relevant data were collected from the hospital's electronic medical record system. Logistic regression nested cubic spline was used to analyze the nonlinear association between preconception BMI and neonatal birth weight. Binary logistic regression was also employed to assess the association between preconception BMI and macrosomia risk. <b>Results:</b> (1) A total of 13 015 pregnant women were examined, revealing an incidence of macrosomia of 6.33% (824/13 015). The preconception BMI of pregnant women in the macrosomia group was significantly higher than that in the non-macrosomia group [(23.1±3.4) vs (21.6±3.1) kg/m<sup>2</sup>], and the age was significantly higher than that in the non-macrosomia group [(32.1±3.6) vs (31.7±3.7) years], the differences were statistically significant (all <i>P</i><0.05). (2) Preconception BMI was positively correlated with neonatal birth weight. Pregnant women with preconception BMI of 15.0 kg/m<sup>2</sup>, 20.0 kg/m<sup>2</sup>, and 25.0 kg/m<sup>2</sup> had decreased birth weight of 121 g (95%<i>CI</i>: 35-183 g) and increased birth weights of 78 g (95%<i>CI</i>: 54-102 g) and 182 g (95%<i>CI</i>: 151-213 g), respectively, compared to those with a preconception BMI of 18.0 kg/m<sup>2</sup>. (3) For each 1.0 kg/m<sup>2</sup> increase in preconception BMI, the risk of macrosomia increased by 14% (<i>OR</i>=1.14, 95%<i>CI</i>: 1.11-1.16; <i>P</i><0.001). When stratified by age, it was observed that elevated preconception BMI significantly increased the incidence of macrosomia in women aged 27-38 years. Among them, the risk of delivering macrosomia among 37 years old pregnant women was most affected by preconception BMI (<i>OR</i>=1.33, 95%<i>CI</i>: 1.17-1.51; <i>P</i><0.001). (4) The stability and sensitivity analysis results showed that the preconception BMI of pregnant women with a preconception BMI of 18.0-<25.0 kg/m<sup>2</sup> had a significant impact on the risk of macrosomia (<i>OR</i>=1.23, 95%<i>CI</i>: 1.17-1.29; <i>P</i><0.001), while the preconception BMI of other preconception BMI stratification pregnant women had no significant impact on the risk of macrosomia (all <i>P</i>>0.05). Hypertension disorders in pregnancy, gestational diabetes mellitus and abnormal blood lipid during pregnancy were not the mediators associated with preconception BMI and macrosomia. After excluding three factors respectively, the impact of preconception BMI on the risk of macrosomia was the same as before (<i>OR</i>=1.14, 95%<i>CI</i>: 1.11-1.16; <i>P</i><0.001). <b>Conclusions:</b> Preconception BMI is linked to neonatal birth wei
目的:探讨孕前体重指数(BMI)对不同年龄组孕妇新生儿体重及巨大儿风险的影响。方法:采用队列研究方法,选取2018年9月1日至2020年3月31日在北京妇产医院进行初次产前评估的孕妇。相关数据从医院的电子病历系统中收集。采用Logistic回归嵌套三次样条分析孕前BMI与新生儿出生体重的非线性关系。还采用二元逻辑回归来评估孕前BMI与巨大儿风险之间的关系。结果:(1)共检查孕妇13 015例,巨大儿发生率为6.33%(824/13 015)。巨大儿组孕妇孕前BMI显著高于非巨大儿组[(23.1±3.4)vs(21.6±3.1)kg/m2],年龄显著高于非巨大儿组[(32.1±3.6)vs(31.7±3.7)岁],差异均有统计学意义(P2、20.0 kg/m2、25.0 kg/m2均使出生体重减少121 g (95%CI: 35 ~ 183 g),出生体重增加78 g (95%CI: 54 ~ 102 g)、182 g (95%CI:与孕前BMI为18.0 kg/m2的孕妇相比,体重分别为151-213 g。(3)孕前BMI每增加1.0 kg/m2,巨大儿风险增加14% (OR=1.14, 95%CI: 1.11-1.16;Por =1.33, 95%ci: 1.17-1.51;P2对巨大儿风险有显著影响(OR=1.23, 95%CI: 1.17-1.29;页> 0.05)。妊娠期高血压疾病、妊娠期糖尿病和妊娠期血脂异常与孕前BMI和巨大儿无关。分别排除三个因素后,孕前BMI对巨大儿风险的影响与孕前相同(OR=1.14, 95%CI: 1.11-1.16;结论:孕前BMI与新生儿体重和巨大儿风险相关,且受孕妇年龄的影响。在临床实践中评估巨大儿的风险时应考虑这两个因素。
{"title":"[Age-stratified association between preconception body mass index and risk of macrosomia at delivery].","authors":"S W Wu, N Zhang","doi":"10.3760/cma.j.cn112141-20240807-00439","DOIUrl":"10.3760/cma.j.cn112141-20240807-00439","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the impact of preconception body mass index (BMI) on neonatal birth weight and the risk of macrosomia in pregnant women across various age groups. &lt;b&gt;Methods:&lt;/b&gt; A cohort study was conducted, selecting pregnant women who underwent their initial prenatal assessment at Beijing Obstetrics and Gynecology Hospital from September 1st, 2018 to March 31st, 2020. Relevant data were collected from the hospital's electronic medical record system. Logistic regression nested cubic spline was used to analyze the nonlinear association between preconception BMI and neonatal birth weight. Binary logistic regression was also employed to assess the association between preconception BMI and macrosomia risk. &lt;b&gt;Results:&lt;/b&gt; (1) A total of 13 015 pregnant women were examined, revealing an incidence of macrosomia of 6.33% (824/13 015). The preconception BMI of pregnant women in the macrosomia group was significantly higher than that in the non-macrosomia group [(23.1±3.4) vs (21.6±3.1) kg/m&lt;sup&gt;2&lt;/sup&gt;], and the age was significantly higher than that in the non-macrosomia group [(32.1±3.6) vs (31.7±3.7) years], the differences were statistically significant (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). (2) Preconception BMI was positively correlated with neonatal birth weight. Pregnant women with preconception BMI of 15.0 kg/m&lt;sup&gt;2&lt;/sup&gt;, 20.0 kg/m&lt;sup&gt;2&lt;/sup&gt;, and 25.0 kg/m&lt;sup&gt;2&lt;/sup&gt; had decreased birth weight of 121 g (95%&lt;i&gt;CI&lt;/i&gt;: 35-183 g) and increased birth weights of 78 g (95%&lt;i&gt;CI&lt;/i&gt;: 54-102 g) and 182 g (95%&lt;i&gt;CI&lt;/i&gt;: 151-213 g), respectively, compared to those with a preconception BMI of 18.0 kg/m&lt;sup&gt;2&lt;/sup&gt;. (3) For each 1.0 kg/m&lt;sup&gt;2&lt;/sup&gt; increase in preconception BMI, the risk of macrosomia increased by 14% (&lt;i&gt;OR&lt;/i&gt;=1.14, 95%&lt;i&gt;CI&lt;/i&gt;: 1.11-1.16; &lt;i&gt;P&lt;/i&gt;&lt;0.001). When stratified by age, it was observed that elevated preconception BMI significantly increased the incidence of macrosomia in women aged 27-38 years. Among them, the risk of delivering macrosomia among 37 years old pregnant women was most affected by preconception BMI (&lt;i&gt;OR&lt;/i&gt;=1.33, 95%&lt;i&gt;CI&lt;/i&gt;: 1.17-1.51; &lt;i&gt;P&lt;/i&gt;&lt;0.001). (4) The stability and sensitivity analysis results showed that the preconception BMI of pregnant women with a preconception BMI of 18.0-&lt;25.0 kg/m&lt;sup&gt;2&lt;/sup&gt; had a significant impact on the risk of macrosomia (&lt;i&gt;OR&lt;/i&gt;=1.23, 95%&lt;i&gt;CI&lt;/i&gt;: 1.17-1.29; &lt;i&gt;P&lt;/i&gt;&lt;0.001), while the preconception BMI of other preconception BMI stratification pregnant women had no significant impact on the risk of macrosomia (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). Hypertension disorders in pregnancy, gestational diabetes mellitus and abnormal blood lipid during pregnancy were not the mediators associated with preconception BMI and macrosomia. After excluding three factors respectively, the impact of preconception BMI on the risk of macrosomia was the same as before (&lt;i&gt;OR&lt;/i&gt;=1.14, 95%&lt;i&gt;CI&lt;/i&gt;: 1.11-1.16; &lt;i&gt;P&lt;/i&gt;&lt;0.001). &lt;b&gt;Conclusions:&lt;/b&gt; Preconception BMI is linked to neonatal birth wei","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"11-17"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research advances of diagnosis and treatment of rectovaginal septum endometriosis]. 【直肠阴道隔子宫内膜异位症的诊断与治疗研究进展】。
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20240805-00436
E N Liu, F Miao, Y F Zhou
{"title":"[Research advances of diagnosis and treatment of rectovaginal septum endometriosis].","authors":"E N Liu, F Miao, Y F Zhou","doi":"10.3760/cma.j.cn112141-20240805-00436","DOIUrl":"10.3760/cma.j.cn112141-20240805-00436","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"66-70"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress in neoadjuvant therapy for epithelial ovarian cancer]. 【上皮性卵巢癌新辅助治疗研究进展】。
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20240930-00532
H Y Dong, L Li
{"title":"[Research progress in neoadjuvant therapy for epithelial ovarian cancer].","authors":"H Y Dong, L Li","doi":"10.3760/cma.j.cn112141-20240930-00532","DOIUrl":"10.3760/cma.j.cn112141-20240930-00532","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"71-78"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Coexistence of development and expectation, balancing tasks and responsibilities]. 【发展与期望并存,任务与责任平衡】。
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20241112-00601
J H Lang
{"title":"[Coexistence of development and expectation, balancing tasks and responsibilities].","authors":"J H Lang","doi":"10.3760/cma.j.cn112141-20241112-00601","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241112-00601","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Expert consensus on complex cesarean section (2024)]. [复杂剖宫产术专家共识(2024)]。
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20241014-00552
{"title":"[Expert consensus on complex cesarean section (2024)].","authors":"","doi":"10.3760/cma.j.cn112141-20241014-00552","DOIUrl":"10.3760/cma.j.cn112141-20241014-00552","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"3-10"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Correlation between uterine volume and intrauterine adhesion: a propensity score matching analysis]. [子宫体积与宫内粘连的相关性:倾向评分匹配分析]。
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20240814-00454
Q Xu, H Duan, Y Y An, L Gan

Objective: To investigate the correlation between uterine volume and intrauterine adhesion (IUA). Methods: From June 2018 to November 2019, totally 7 007 patients who underwent hysteroscopy in outpatient operating rooms of Gynecological Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital were retrospectively analyzed. Patients of reproductive age with IUA without uterine fibroids and adenomyosis were selected as IUA group, and patients of reproductive age without uterine fibroids and adenomyosis without IUA during the same period were selected as the control group. The propensity score matching (PSM) method was used to perform 1∶1 matching for the two groups of patients, matching variables included age, height, weight, body mass index (BMI), gravidity, parity, and number of abortion curettage. Whether there was any difference in uterine volume between the two groups of patients was compared, and whether uterine volume was an influencing factor of IUA was explored. The patients in IUA group were also categorized into mild, moderate and severe to explore whether uterine volume influenced the severity of IUA. Results: (1) After inclusion and exclusion criteria, 351 patients were included in IUA group and 2 986 patients in the control group. With PSM, 327 patients in IUA group and 327 patients in the control group were finally enrolled in this study. There were no statistically significant differences in age, height, weight, BMI, gravidity, parity, and number of abortion curettage between the two groups of patients after matching (all P>0.05). (2) After PSM, there was a significant difference between the uterine volume of IUA group (median: 44.23 cm3) and the uterine volume of the control group (median: 57.20 cm3; P<0.001). (3) Reduced uterine volume (OR=0.961, 95%CI: 0.952-0.970) was an independent risk factor for IUA (P<0.001). (4) Uterine volume had a significant effect on the severity of IUA (P<0.001), the larger the uterine volume (B=-0.030, 95%CI: -0.044 to -0.017), the less severe the IUA. Conclusions: Reduced uterine volume is an independent risk factor for IUA, and uterine volume has a significant effect on the severity of IUA. In patients with small uterine volume size, primary and secondary prevention of IUA should be emphasized.

目的:探讨子宫体积与宫内粘连(IUA)的关系。方法:回顾性分析2018年6月至2019年11月在北京妇产医院妇科微创中心门诊手术室行宫腔镜检查的患者7 007例。选择育龄期IUA且无子宫肌瘤、子宫腺肌症的患者为IUA组,育龄期无子宫肌瘤、子宫腺肌症且同期未IUA的患者为对照组。采用倾向评分匹配(PSM)法对两组患者进行1∶1匹配,匹配变量为年龄、身高、体重、体重指数(BMI)、胎次、胎次、流产刮宫次数。比较两组患者子宫体积有无差异,探讨子宫体积是否为IUA的影响因素。将IUA组患者分为轻、中、重度,探讨子宫体积是否影响IUA的严重程度。结果:(1)经纳入、排除标准后,IUA组351例,对照组2986例。合并PSM后,IUA组327例患者和对照组327例患者最终入组。配对后两组患者的年龄、身高、体重、BMI、胎次、胎次、刮宫次数比较,差异均无统计学意义(P < 0.05)。(2)经PSM后,IUA组子宫体积(中位数:44.23 cm3)与对照组(中位数:57.20 cm3)差异有统计学意义;POR=0.961, 95%CI: 0.952 ~ 0.970)是IUA的独立危险因素(PPB=-0.030, 95%CI: -0.044 ~ -0.017), IUA越轻。结论:子宫体积缩小是IUA的独立危险因素,子宫体积对IUA的严重程度有显著影响。对于子宫体积小的患者,应重视IUA的一级和二级预防。
{"title":"[Correlation between uterine volume and intrauterine adhesion: a propensity score matching analysis].","authors":"Q Xu, H Duan, Y Y An, L Gan","doi":"10.3760/cma.j.cn112141-20240814-00454","DOIUrl":"10.3760/cma.j.cn112141-20240814-00454","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the correlation between uterine volume and intrauterine adhesion (IUA). <b>Methods:</b> From June 2018 to November 2019, totally 7 007 patients who underwent hysteroscopy in outpatient operating rooms of Gynecological Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital were retrospectively analyzed<i>.</i> Patients of reproductive age with IUA without uterine fibroids and adenomyosis were selected as IUA group, and patients of reproductive age without uterine fibroids and adenomyosis without IUA during the same period were selected as the control group. The propensity score matching (PSM) method was used to perform 1∶1 matching for the two groups of patients, matching variables included age, height, weight, body mass index (BMI), gravidity, parity, and number of abortion curettage. Whether there was any difference in uterine volume between the two groups of patients was compared, and whether uterine volume was an influencing factor of IUA was explored. The patients in IUA group were also categorized into mild, moderate and severe to explore whether uterine volume influenced the severity of IUA. <b>Results:</b> (1) After inclusion and exclusion criteria, 351 patients were included in IUA group and 2 986 patients in the control group. With PSM, 327 patients in IUA group and 327 patients in the control group were finally enrolled in this study. There were no statistically significant differences in age, height, weight, BMI, gravidity, parity, and number of abortion curettage between the two groups of patients after matching (all <i>P></i>0.05). (2) After PSM, there was a significant difference between the uterine volume of IUA group (median: 44.23 cm<sup>3</sup>) and the uterine volume of the control group (median: 57.20 cm<sup>3</sup>; <i>P</i><0.001). (3) Reduced uterine volume (<i>OR</i>=0.961, 95%<i>CI</i>: 0.952-0.970) was an independent risk factor for IUA (<i>P</i><0.001). (4) Uterine volume had a significant effect on the severity of IUA (<i>P</i><0.001), the larger the uterine volume (<i>B</i>=-0.030, 95%<i>CI</i>: -0.044 to -0.017), the less severe the IUA. <b>Conclusions:</b> Reduced uterine volume is an independent risk factor for IUA, and uterine volume has a significant effect on the severity of IUA. In patients with small uterine volume size, primary and secondary prevention of IUA should be emphasized.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"18-23"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical characteristics and prognosis of ovarian juvenile granulosa cell tumors]. 卵巢幼年性颗粒细胞瘤的临床特点及预后
Pub Date : 2025-01-25 DOI: 10.3760/cma.j.cn112141-20240825-00256
X Ma, G Y Zhang, Z Li
<p><p><b>Objective:</b> To analyze the clinical characteristics, treatments, and prognosis of patients with ovarian juvenile granulosa cell tumor (JGCT). <b>Methods:</b> Clinical and pathological data, and follow-up information of 34 patients diagnosed with JGCT from 2000 to 2021 were collected from the surveillance, epidemiology, and end results (SEER) database. A retrospective analysis was conducted to summarize the patients' clinical and pathological characteristics, treatments, and prognosis. Propensity score matching (PSM) was used to match the JGCT cases with adult granulosa cell tumor (AGCT) cases in SEER database. A total of 96 patients with ovarian granulosa cell tumor (OGCT), including 32 cases of JGCT and 64 cases of AGCT, were enrolled in a matched cohort analysis. Univariate and multivariate Cox regression analysis were performed on the matched cohort to explore the risk factors for overall survival. Kaplan-Meier curves and the log-rank test were used to compare the survival outcomes between JGCT and AGCT. <b>Results:</b> (1) The median age at diagnosis for the 34 JGCT patients was 19.5 years (ranged: 1-48 years), with 3 patients aged ≤10 years, 16 patients aged 11-20 years, 11 patients aged 21-30 years, and 4 patients aged >30 years. Tumors originated unilaterally in 33 patients, with only 1 case originating bilaterally. The maximum tumor diameter was recorded in 26 patients, with a median size of 12.4 cm (ranged: 3.5-40.0 cm). According to the 2014 International Federation of Gynecology and Obstetrics (FIGO) staging system, 19 patients were diagnosed with stage Ⅰ (including 10 cases with stage Ⅰa and 9 cases with stage Ⅰc), 4 patients with stage Ⅱ, 8 patients with stage Ⅲ, and 3 patients with stage Ⅳ. Two patients did not undergo surgery for the resection of lesions. Stage Ⅰ patients (15/19) underwent fertility-sparing surgery, while stage Ⅱ-Ⅲ patients underwent either fertility-sparing surgery or cytoreductive surgery (6 cases each). Stage Ⅳ patients underwent cytoreductive surgery (2 cases). Lymph node dissection was performed in 10 patients, among which only 1 patient with positive lymph nodes metastasis. None of the 34 patients received radiotherapy, while 18 patients received adjuvant chemotherapy (included neoadjuvant chemotherapy and postoperative adjuvant chemotherapy). The proportion of stage Ⅰ patients receiving adjuvant chemotherapy was relatively low, with only 4 out of 19 patients (including 2 out of 10 cases for stage Ⅰa and 2 out of 9 cases for stage Ⅰc). The proportions of patients receiving adjuvant chemotherapy for stages Ⅱ, Ⅲ and Ⅳ were 3 out of 4 cases, 8 out of 8 cases, and 3 out of 3 cases, respectively. The follow-up ended in December 2021, with 20 patients alive and 14 dead. The survival rate for ovarian JGCT patients was 59% (20/34). Among them, the survival rate for stage Ⅰ patients was 16/19, while for stage Ⅱ-Ⅳ patients, it was 4/15; there was a statistically significant difference (<i>P</i>=0.002). Amon
目的:分析卵巢幼年颗粒细胞瘤(JGCT)的临床特点、治疗及预后。方法:从监测、流行病学和最终结果(SEER)数据库中收集2000 - 2021年34例诊断为JGCT的患者的临床、病理资料及随访信息。回顾性分析患者的临床病理特点、治疗方法及预后。采用倾向评分匹配(PSM)将JGCT病例与SEER数据库中的成人颗粒细胞瘤(AGCT)病例进行匹配。配对队列分析共纳入96例卵巢颗粒细胞瘤(OGCT)患者,其中JGCT 32例,AGCT 64例。对匹配队列进行单因素和多因素Cox回归分析,探讨影响总生存的危险因素。采用Kaplan-Meier曲线和log-rank检验比较JGCT和AGCT的生存结局。结果:(1)34例JGCT患者的中位诊断年龄为19.5岁(范围1 ~ 48岁),其中≤10岁3例,11 ~ 20岁16例,21 ~ 30岁11例,bb0 ~ 30岁4例。33例患者肿瘤起源于单侧,只有1例起源于双侧。最大肿瘤直径26例,中位直径12.4 cm(范围:3.5-40.0 cm)。根据2014年国际妇产联合会(FIGO)分期系统,19例患者诊断为Ⅰ期(其中Ⅰa期10例,Ⅰc期9例),Ⅱ期4例,Ⅲ期8例,Ⅳ期3例。2例患者未行手术切除病灶。Ⅰ期患者(15/19)行保留生育能力手术,Ⅱ-Ⅲ期患者分别行保留生育能力手术或细胞减少手术(各6例)。Ⅳ期患者行细胞减缩手术2例。10例患者行淋巴结清扫,其中仅有1例淋巴结转移阳性。34例患者均未接受放疗,18例患者接受了辅助化疗(包括新辅助化疗和术后辅助化疗)。Ⅰ期患者接受辅助化疗的比例相对较低,19例患者中只有4例(其中Ⅰa期10例中有2例,Ⅰc期9例中有2例)。Ⅱ、Ⅲ、Ⅳ期患者接受辅助化疗的比例分别为3 / 4、8 / 8、3 / 3。随访于2021年12月结束,20名患者存活,14名患者死亡。卵巢JGCT患者生存率为59%(20/34)。其中Ⅰ期患者生存率为16/19,Ⅱ-Ⅳ期患者生存率为4/15;差异有统计学意义(P=0.002)。在Ⅱ-Ⅲ期患者中,随访结束时,接受保留生育能力手术的患者生存率为1/6,而接受细胞减少手术的患者生存率为3/6 (P=0.546)。(2) 96例经PSM方法匹配的OGCT患者中,64例卵巢AGCT患者随访期间死亡5例,存活59例,随访结束时生存率为92%(59/64)。32例卵巢JGCT患者中,死亡13例,存活19例,随访结束时生存率为59%(19/32),与AGCT组差异有统计学意义(ppp结论:卵巢JGCT多发生在青少年和年轻女性中。淋巴结转移相对罕见,治疗主要包括手术和辅助化疗。大多数卵巢JGCT患者诊断为Ⅰ期,预后良好。建议保留生育能力的手术,包括患侧输卵管卵巢切除术加综合分期手术,或第二次手术以达到综合分期。对于Ⅱ-Ⅳ期卵巢JGCT患者,预后相对较差,应谨慎考虑保留生育能力的手术。卵巢JGCT患者预后较卵巢AGCT患者差。
{"title":"[Clinical characteristics and prognosis of ovarian juvenile granulosa cell tumors].","authors":"X Ma, G Y Zhang, Z Li","doi":"10.3760/cma.j.cn112141-20240825-00256","DOIUrl":"10.3760/cma.j.cn112141-20240825-00256","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To analyze the clinical characteristics, treatments, and prognosis of patients with ovarian juvenile granulosa cell tumor (JGCT). &lt;b&gt;Methods:&lt;/b&gt; Clinical and pathological data, and follow-up information of 34 patients diagnosed with JGCT from 2000 to 2021 were collected from the surveillance, epidemiology, and end results (SEER) database. A retrospective analysis was conducted to summarize the patients' clinical and pathological characteristics, treatments, and prognosis. Propensity score matching (PSM) was used to match the JGCT cases with adult granulosa cell tumor (AGCT) cases in SEER database. A total of 96 patients with ovarian granulosa cell tumor (OGCT), including 32 cases of JGCT and 64 cases of AGCT, were enrolled in a matched cohort analysis. Univariate and multivariate Cox regression analysis were performed on the matched cohort to explore the risk factors for overall survival. Kaplan-Meier curves and the log-rank test were used to compare the survival outcomes between JGCT and AGCT. &lt;b&gt;Results:&lt;/b&gt; (1) The median age at diagnosis for the 34 JGCT patients was 19.5 years (ranged: 1-48 years), with 3 patients aged ≤10 years, 16 patients aged 11-20 years, 11 patients aged 21-30 years, and 4 patients aged &gt;30 years. Tumors originated unilaterally in 33 patients, with only 1 case originating bilaterally. The maximum tumor diameter was recorded in 26 patients, with a median size of 12.4 cm (ranged: 3.5-40.0 cm). According to the 2014 International Federation of Gynecology and Obstetrics (FIGO) staging system, 19 patients were diagnosed with stage Ⅰ (including 10 cases with stage Ⅰa and 9 cases with stage Ⅰc), 4 patients with stage Ⅱ, 8 patients with stage Ⅲ, and 3 patients with stage Ⅳ. Two patients did not undergo surgery for the resection of lesions. Stage Ⅰ patients (15/19) underwent fertility-sparing surgery, while stage Ⅱ-Ⅲ patients underwent either fertility-sparing surgery or cytoreductive surgery (6 cases each). Stage Ⅳ patients underwent cytoreductive surgery (2 cases). Lymph node dissection was performed in 10 patients, among which only 1 patient with positive lymph nodes metastasis. None of the 34 patients received radiotherapy, while 18 patients received adjuvant chemotherapy (included neoadjuvant chemotherapy and postoperative adjuvant chemotherapy). The proportion of stage Ⅰ patients receiving adjuvant chemotherapy was relatively low, with only 4 out of 19 patients (including 2 out of 10 cases for stage Ⅰa and 2 out of 9 cases for stage Ⅰc). The proportions of patients receiving adjuvant chemotherapy for stages Ⅱ, Ⅲ and Ⅳ were 3 out of 4 cases, 8 out of 8 cases, and 3 out of 3 cases, respectively. The follow-up ended in December 2021, with 20 patients alive and 14 dead. The survival rate for ovarian JGCT patients was 59% (20/34). Among them, the survival rate for stage Ⅰ patients was 16/19, while for stage Ⅱ-Ⅳ patients, it was 4/15; there was a statistically significant difference (&lt;i&gt;P&lt;/i&gt;=0.002). Amon","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 1","pages":"34-45"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Guideline of cervical ripening and labor induction during the third trimester pregnancy (2024)]. [妊娠三个月宫颈成熟和引产指南(2024 年)]。
Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn112141-20240707-00381
{"title":"[Guideline of cervical ripening and labor induction during the third trimester pregnancy (2024)].","authors":"","doi":"10.3760/cma.j.cn112141-20240707-00381","DOIUrl":"10.3760/cma.j.cn112141-20240707-00381","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 11","pages":"819-828"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Potential of new self-crosslinked hyaluronic acid gel on the recovery of endometrium after artificial abortion: a multicenter, prospective randomized controlled trial]. [新型自交联透明质酸凝胶对人工流产后子宫内膜恢复的潜力:一项多中心、前瞻性随机对照试验]。
Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn112141-20240906-00493
C Y Li, L R Teng, Q Lin, L P Zhao, Y X Zhu, X Mi, Z N Wang, X Y Wang, L S Zhang, D Han, L L Ma, W P Bai, J M Wang, J Ni, H P Shen, Q F Chen, H M Xu, C C Ren, J Jiang, G Y Liu, P Peng, X Y Liu

Objective: To evaluate the impact of self-crosslinked hyaluronic acid (SCH) gel on endometrium recovery after artificial abortion. Methods: A multicenter, prospective randomized controlled trial was conducted across 18 hospitals from December 2021 to February 2023, involving 382 women who underwent artificial abortion. Participants were randomly allocated to receive either treatment with SCH gel (SCH group) or no treatment (control group) in a 1∶1 ratio. The primary outcome was endometrium thickness in 14 to 18 days after the first postoperative menstruation. Secondary outcomes included changes in menstrual volume during the first postoperative menstruation, menstruation resumption within 6 postoperative weeks, time to menstruation resumption, duration of the first postoperative menstruation, and incidence of dysmenorrhea. Results: Baseline characteristics of participants were comparable between the two groups (all P>0.05), with 95.3% (182/191) in SCH group and 92.7% (177/191) in the control group completed the study. The postoperative endometrial thickness in SCH group was significantly greater than that in the control group [(9.78±3.15) vs (8.95±2.32) mm; P=0.005]. SCH group also had significantly fewer participants with reduced menstrual volume [23 cases (12.6%, 23/182) vs 31 cases (17.5%, 31/177); P=0.038]. Although SCH group experienced less dysmenorrhea during the first postoperative menstrual period, this difference was not statistically significant [28.5% (51/179) vs 37.1% (65/175); P=0.083]. Outcomes were similar between SCH group and the control group regarding the proportion of participants who resumed menstruation within 6 weeks postoperatively, time to menstruation resumption, and duration of the first postoperative menstruation (P=0.792, 0.485, and 0.254, respectively). No serious adverse events were observed during the study period, and no adverse events were attributed to SCH gel treatment. Conclusion: The application of SCH gel after artificial abortion is safe and might aid in the recovery of the endometrium.

目的:评估自交联透明质酸凝胶对人工流产后子宫内膜恢复的影响:评估自交联透明质酸(SCH)凝胶对人工流产后子宫内膜恢复的影响。方法:在 18 家医院开展一项多中心、前瞻性随机对照试验:2021年12月至2023年2月期间,在18家医院开展了一项多中心、前瞻性随机对照试验,共有382名女性接受了人工流产。参与者按1∶1的比例随机分配接受SCH凝胶治疗(SCH组)或不接受治疗(对照组)。主要结果是术后第一次月经来潮后14至18天的子宫内膜厚度。次要结果包括术后首次月经期间月经量的变化、术后6周内月经恢复情况、月经恢复时间、术后首次月经持续时间和痛经发生率。研究结果两组参与者的基线特征具有可比性(P均大于0.05),SCH组95.3%(182/191)和对照组92.7%(177/191)的参与者完成了研究。SCH组术后子宫内膜厚度明显高于对照组[(9.78±3.15) mm vs (8.95±2.32) mm; P=0.005]。SCH组中月经量减少的人数也明显少于对照组[23例(12.6%,23/182) vs 31例(17.5%,31/177);P=0.038]。虽然SCH组在术后第一次月经期间出现痛经的人数较少,但这一差异在统计学上并不显著[28.5%(51/179) vs 37.1%(65/175);P=0.083]。在术后6周内恢复月经的参与者比例、恢复月经的时间以及术后首次月经持续时间方面,SCH组与对照组的结果相似(P分别为0.792、0.485和0.254)。研究期间未观察到严重不良事件,也没有不良事件归因于SCH凝胶治疗。结论人工流产后使用SCH凝胶是安全的,可能有助于子宫内膜的恢复。
{"title":"[Potential of new self-crosslinked hyaluronic acid gel on the recovery of endometrium after artificial abortion: a multicenter, prospective randomized controlled trial].","authors":"C Y Li, L R Teng, Q Lin, L P Zhao, Y X Zhu, X Mi, Z N Wang, X Y Wang, L S Zhang, D Han, L L Ma, W P Bai, J M Wang, J Ni, H P Shen, Q F Chen, H M Xu, C C Ren, J Jiang, G Y Liu, P Peng, X Y Liu","doi":"10.3760/cma.j.cn112141-20240906-00493","DOIUrl":"10.3760/cma.j.cn112141-20240906-00493","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the impact of self-crosslinked hyaluronic acid (SCH) gel on endometrium recovery after artificial abortion. <b>Methods:</b> A multicenter, prospective randomized controlled trial was conducted across 18 hospitals from December 2021 to February 2023, involving 382 women who underwent artificial abortion. Participants were randomly allocated to receive either treatment with SCH gel (SCH group) or no treatment (control group) in a 1∶1 ratio. The primary outcome was endometrium thickness in 14 to 18 days after the first postoperative menstruation. Secondary outcomes included changes in menstrual volume during the first postoperative menstruation, menstruation resumption within 6 postoperative weeks, time to menstruation resumption, duration of the first postoperative menstruation, and incidence of dysmenorrhea. <b>Results:</b> Baseline characteristics of participants were comparable between the two groups (all <i>P</i>>0.05), with 95.3% (182/191) in SCH group and 92.7% (177/191) in the control group completed the study. The postoperative endometrial thickness in SCH group was significantly greater than that in the control group [(9.78±3.15) vs (8.95±2.32) mm; <i>P</i>=0.005]. SCH group also had significantly fewer participants with reduced menstrual volume [23 cases (12.6%, 23/182) vs 31 cases (17.5%, 31/177); <i>P</i>=0.038]. Although SCH group experienced less dysmenorrhea during the first postoperative menstrual period, this difference was not statistically significant [28.5% (51/179) vs 37.1% (65/175); <i>P</i>=0.083]. Outcomes were similar between SCH group and the control group regarding the proportion of participants who resumed menstruation within 6 weeks postoperatively, time to menstruation resumption, and duration of the first postoperative menstruation (<i>P</i>=0.792, 0.485, and 0.254, respectively). No serious adverse events were observed during the study period, and no adverse events were attributed to SCH gel treatment. <b>Conclusion:</b> The application of SCH gel after artificial abortion is safe and might aid in the recovery of the endometrium.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 11","pages":"864-870"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effect of FCN gene single nucleotide polymorphism on the susceptibility of pre-eclampsia in Han nationality pregnant women]. [FCN基因单核苷酸多态性对汉族孕妇子痫前期易感性的影响]。
Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn112141-20240626-00361
J Y Tan, Y L Tan, B Yang, W Yang, C L Yuan, X J Mi, F E Cai, Y J Gan, Y J He

Objective: To investigate the effect of single nucleotide polymorphism (SNP) of FCN gene on the susceptibility of pre-eclampsia (PE) in Han nationality pregnant women. Methods: A total of 274 PE pregnant women (PE group) and 154 healthy pregnant women (control group) admitted to Boai Hospital of Zhongshan, Affiliated Hospital to Southern Medical University from October 2020 to October 2022 were collected. The general information, medical history, reproductive history, blood pressure, body mass index and blood biochemical indicators before delivery were compared between the two groups. Twenty-three SNP loci of FCN gene family were genotyped by time-of-flight mass spectrometry, and the serum levels of ficolins (ficolin-1, -2 and -3) were detected by enzyme-linked immunosorbent assay. Results: (1) Compared with the control group, the body mass index, mean arterial pressure, gestational age at delivery, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, direct bilirubin, albumin, and C-reactive protein in the PE group were significantly higher than those in the control group (all P<0.05). The levels of N-terminal pro-B type natriuretic peptide (NT-proBNP), placental growth factor (PlGF) and human soluble vascular endothelial growth factor receptor-1 (sFlt-1) were significantly different between the two groups (all P<0.05). (2) Among the 23 SNP loci in FCN gene family, 18 loci were in Hardy-Weinberg genetic equilibrium, including 5 loci in FCN1 gene, 10 loci in FCN2 gene, and 3 loci in FCN3 gene. Five loci that did not conform to Hardy-Weinberg genetic equilibrium were not included in the subsequent analysis. Compared with the control group, the genotype distribution of 3 loci of FCN2 gene (rs7872508, rs11103563, rs73664188) and 1 locus of FCN3 gene (rs3813800) in the PE group were significantly different (all P<0.05). After Bonferroni correction, only the genotype distribution of rs7872508 and rs73664188 in FCN2 gene were statistically different between the PE group and the control group (all P<0.05). Further analysis showed that for the rs7872508 locus of FCN2 gene, compared with GG genotype, genotype GT (OR=3.025, 95%CI: 1.080-8.471) and TT (OR=4.777, 95%CI: 1.758-12.979) both significantly increased the risk of PE (both P<0.05). For rs73664188 locus of FCN2 gene, compared with TT genotype, genotype TC (OR=0.510, 95%CI: 0.334-0.778) significantly reduced the risk of PE (P<0.05). (3) Compared with the control group, the serum levels of ficolin-1 and ficolin-2 in pregnant women in the PE group were significantly reduced (both P<0.05), while the level of ficolin-3 showed no significant change (P=0.271). Correlation analysis showed that the serum levels of ficolin-2 in pregnant women in the PE group were significantly positively correlated with PlGF level (r=0.321, P<0.001), and significantly

研究目的研究FCN基因单核苷酸多态性(SNP)对汉族孕妇子痫前期(PE)易感性的影响。方法收集2020年10月至2022年10月南方医科大学附属中山博爱医院收治的274名子痫前期孕妇(PE组)和154名健康孕妇(对照组)。比较两组孕妇的一般资料、病史、生育史、血压、体重指数和产前血液生化指标。采用飞行时间质谱法对23个FCN基因家族SNP位点进行基因分型,并采用酶联免疫吸附法检测血清中非考酚类化合物(ficolin-1、-2和-3)的水平。结果:(1)与对照组相比,PE 组的体重指数、平均动脉压、产时胎龄、血尿素氮、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、直接胆红素、白蛋白、C 反应蛋白均明显高于对照组(均 PPPPOR=3.025,95%CI:1.080-8.471)和TT(OR=4.777,95%CI:1.758-12.979)均显著增加PE的风险(均POR=0.510,95%CI:0.334-0.778)显著降低PE的风险(PPP=0.271)。相关分析表明,PE 组孕妇血清中的 ficolin-2 水平与 PlGF 水平(r=0.321,Pr=-0.187,P=0.002)和 NT-proBNP 水平(r=-0.392,PPPConclusion)呈显著正相关:FCN基因家族中FCN2基因的SNP可能与PE易感性有关,并对PE孕妇血清ficolin-2水平有影响。
{"title":"[Effect of FCN gene single nucleotide polymorphism on the susceptibility of pre-eclampsia in Han nationality pregnant women].","authors":"J Y Tan, Y L Tan, B Yang, W Yang, C L Yuan, X J Mi, F E Cai, Y J Gan, Y J He","doi":"10.3760/cma.j.cn112141-20240626-00361","DOIUrl":"10.3760/cma.j.cn112141-20240626-00361","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect of single nucleotide polymorphism (SNP) of FCN gene on the susceptibility of pre-eclampsia (PE) in Han nationality pregnant women. <b>Methods:</b> A total of 274 PE pregnant women (PE group) and 154 healthy pregnant women (control group) admitted to Boai Hospital of Zhongshan, Affiliated Hospital to Southern Medical University from October 2020 to October 2022 were collected. The general information, medical history, reproductive history, blood pressure, body mass index and blood biochemical indicators before delivery were compared between the two groups. Twenty-three SNP loci of FCN gene family were genotyped by time-of-flight mass spectrometry, and the serum levels of ficolins (ficolin-1, -2 and -3) were detected by enzyme-linked immunosorbent assay. <b>Results:</b> (1) Compared with the control group, the body mass index, mean arterial pressure, gestational age at delivery, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, direct bilirubin, albumin, and C-reactive protein in the PE group were significantly higher than those in the control group (all <i>P</i><0.05). The levels of N-terminal pro-B type natriuretic peptide (NT-proBNP), placental growth factor (PlGF) and human soluble vascular endothelial growth factor receptor-1 (sFlt-1) were significantly different between the two groups (all <i>P</i><0.05). (2) Among the 23 SNP loci in FCN gene family, 18 loci were in Hardy-Weinberg genetic equilibrium, including 5 loci in FCN1 gene, 10 loci in FCN2 gene, and 3 loci in FCN3 gene. Five loci that did not conform to Hardy-Weinberg genetic equilibrium were not included in the subsequent analysis. Compared with the control group, the genotype distribution of 3 loci of FCN2 gene (rs7872508, rs11103563, rs73664188) and 1 locus of FCN3 gene (rs3813800) in the PE group were significantly different (all <i>P</i><0.05). After Bonferroni correction, only the genotype distribution of rs7872508 and rs73664188 in FCN2 gene were statistically different between the PE group and the control group (all <i>P</i><0.05). Further analysis showed that for the rs7872508 locus of FCN2 gene, compared with GG genotype, genotype GT (<i>OR</i>=3.025, 95%<i>CI</i>: 1.080-8.471) and TT (<i>OR</i>=4.777, 95%<i>CI</i>: 1.758-12.979) both significantly increased the risk of PE (both <i>P</i><0.05). For rs73664188 locus of FCN2 gene, compared with TT genotype, genotype TC (<i>OR</i>=0.510, 95%<i>CI</i>: 0.334-0.778) significantly reduced the risk of PE (<i>P</i><0.05). (3) Compared with the control group, the serum levels of ficolin-1 and ficolin-2 in pregnant women in the PE group were significantly reduced (both <i>P</i><0.05), while the level of ficolin-3 showed no significant change (<i>P</i>=0.271). Correlation analysis showed that the serum levels of ficolin-2 in pregnant women in the PE group were significantly positively correlated with PlGF level (<i>r</i>=0.321, <i>P</i><0.001), and significantly","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 11","pages":"839-847"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华妇产科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1